13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Research home > Beat Cancer Project > Structure-based design of novel IL-3 variants with selective function in cancer therapy

    Structure-based design of novel IL-3 variants with selective function in cancer therapy

    Dr Timothy Hercus

    Cancer patients often have insufficient white blood cells and as a result are vulnerable to a range of fatal infections. Interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are proteins that regulate the production and function of white blood cells that protect our body from infections but can have undesirable side-effects. Through understanding how IL-3 and GM-CSF function, we will develop selective variants that better stimulate white blood cell production.



  • Apply for funding

    Apply for funding

    Find out more about applications for funding.

  • Cancer statistics

    Cancer statistics

    Access the latest cancer statistics for South Australia

  • Clinical trials

    Clinical trials

    Access the list of current clinical trials taking place in South Australia.